X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Holly Campbell

Holly Campbell Holly Campbell is a deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.

Recent Posts

America’s biopharmaceutical companies are working around the clock to beat coronavirus

By Holly Campbell  |    March 20, 2020
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) underscored the industry’s commitment to finding solutions to prevent,...   Read More

PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

By Holly Campbell  |    March 3, 2020
Yesterday, PhRMA submitted comments on the Department of Health & Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameters proposed rule. The proposed rule would hurt  patients’ ability...   Read More

Nearly 50% of brand medicine spending goes to the supply chain and others

By Holly Campbell  |    January 9, 2020
Nearly 50% of total spending on brand medicines – the sum of all payments made at the pharmacy or paid on a claim to a health care provider – went to the supply chain and other entities in 2018,...   Read More

New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018

By Holly Campbell  |    December 6, 2019
According to new data from the National Health Expenditures (NHE), retail medicine prices declined by 1% and retail medicine spending grew just 2.5% in 2018. To put that in context, hospital...   Read More

PhRMA CEO in STAT: Pelosi’s drug pricing plan puts medical innovation at risk

By Holly Campbell  |    October 17, 2019
The following op-ed was authored by PhRMA president and CEO Stephen J. Ubl and published in STAT First Opinion here on October 17, 2019. The future of medical innovation in America is at a...   Read More

More evidence that medicine prices are growing at slowest rate in decades

By Holly Campbell  |    October 4, 2019
This week the White House Council of Economic Advisers (CEA) released yet another report showing that medicine prices are growing at the slowest rate in decades. The report, “Measuring...   Read More

The truth about the marketing and promotion of medicines

By Holly Campbell  |    October 3, 2019
Despite what critics say, the U.S. biopharmaceutical industry spends three times more on the research and development (R&D) of new treatments and cures than on the marketing and promotion of...   Read More

Survey shows out-of-pocket costs top health care concern for voters

By Holly Campbell  |    October 2, 2019
A recent national survey of 800 registered voters conducted by Public Opinion Strategies shows that health insurance premiums, deductibles and copays are the top health care concerns for...   Read More

Study finds hospitals continue to mark up medicines up to 500% of their cost

By Holly Campbell  |    July 9, 2019
A new analysis from the Moran Company found hospitals continue to charge, on average, five times their cost for medicines, driving up cost sharing and premiums for patients across the country....   Read More

Three reasons why the latest Rx Savings Solutions analysis is misleading

By Holly Campbell  |    July 2, 2019
Yesterday, multiple news outlets featured data from Rx Savings Solutions on medicine price trends. These data reflect list price increases, ignoring the significant rebates and discounts on...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates